中国肝脏病杂志（电子版）
中國肝髒病雜誌（電子版）
중국간장병잡지（전자판）
CHINESE JOURNAL OF LIVER DISEASES(ELECTRONIC VERSION)
2014年
4期
71-74
,共4页
肝硬化%肝炎,乙型%阿德福韦酯
肝硬化%肝炎,乙型%阿德福韋酯
간경화%간염,을형%아덕복위지
Liver cirrhosis%Hepatitis B%Adefovir dipivoxil
目的：观察阿德福韦酯（ADV）联合安络化纤丸治疗乙型肝炎肝硬化代偿期的疗效和安全性。方法76例乙型肝炎代偿期肝硬化患者随机分为单用ADV的对照组及ADV ＋安络化纤丸联合治疗的治疗组，两组患者疗程均为48周，治疗后观察两组患者肝功能、HBV及肝纤维化指标。结果治疗48周，联合治疗组肝功能均有好转，ALT、ALB及TBil与治疗前比较（P均＜0.05），差异均有统计学意义。联合治疗组治疗后血清HBV DNA、HBeAg低于检测下限的比率及HBeAg/抗HBe转换率较治疗前升高，差异均有统计学意义（P均＜0.01）。联合治疗组肝纤维化各项指标下降值与对照组比较更显著（P均＜0.05），差异均有统计学意义；其治疗后超声检测脾脏厚度及长径与治疗前比较均有减低，下降幅度与对照组比较更显著（P＜0.05）。结论 ADV联合安络化纤丸治疗乙型肝炎肝硬化有明显抗纤维化作用，其疗效优于单用ADV。
目的：觀察阿德福韋酯（ADV）聯閤安絡化纖汍治療乙型肝炎肝硬化代償期的療效和安全性。方法76例乙型肝炎代償期肝硬化患者隨機分為單用ADV的對照組及ADV ＋安絡化纖汍聯閤治療的治療組，兩組患者療程均為48週，治療後觀察兩組患者肝功能、HBV及肝纖維化指標。結果治療48週，聯閤治療組肝功能均有好轉，ALT、ALB及TBil與治療前比較（P均＜0.05），差異均有統計學意義。聯閤治療組治療後血清HBV DNA、HBeAg低于檢測下限的比率及HBeAg/抗HBe轉換率較治療前升高，差異均有統計學意義（P均＜0.01）。聯閤治療組肝纖維化各項指標下降值與對照組比較更顯著（P均＜0.05），差異均有統計學意義；其治療後超聲檢測脾髒厚度及長徑與治療前比較均有減低，下降幅度與對照組比較更顯著（P＜0.05）。結論 ADV聯閤安絡化纖汍治療乙型肝炎肝硬化有明顯抗纖維化作用，其療效優于單用ADV。
목적：관찰아덕복위지（ADV）연합안락화섬환치료을형간염간경화대상기적료효화안전성。방법76례을형간염대상기간경화환자수궤분위단용ADV적대조조급ADV ＋안락화섬환연합치료적치료조，량조환자료정균위48주，치료후관찰량조환자간공능、HBV급간섬유화지표。결과치료48주，연합치료조간공능균유호전，ALT、ALB급TBil여치료전비교（P균＜0.05），차이균유통계학의의。연합치료조치료후혈청HBV DNA、HBeAg저우검측하한적비솔급HBeAg/항HBe전환솔교치료전승고，차이균유통계학의의（P균＜0.01）。연합치료조간섬유화각항지표하강치여대조조비교경현저（P균＜0.05），차이균유통계학의의；기치료후초성검측비장후도급장경여치료전비교균유감저，하강폭도여대조조비교경현저（P＜0.05）。결론 ADV연합안락화섬환치료을형간염간경화유명현항섬유화작용，기료효우우단용ADV。
Objective To investigate the efficacy and safety of adefovir dipivoxil (ADV) combined with Anluohuaxian pills in treating HBV related compensated cirrhosis. Methods Total of 76 patients with compensated cirrhosis of hepatitis B virus infection were randomly assigned to treatment group (using ADV combined with Anluohuaxian pills) and control group (only using ADV). The treatment lasted 48 weeks. And the liver function and index of HBV and liver ifbrosis were observed after treatment. Results For treatment group, at week 48, the liver function were all better than before, and there were statistically significant difference in ALT, ALB and TBil between before and after treatment (P<0.05). Also there were statistically significant difference in HBV DNA negative rate, HBeAg negative rate and HBeAg seroconversion rate between before and after treatment (P<0.01). The decreased value of index of liver fibrosis were more obvious than those of the control group (P < 0.05). The decreased value in ultrasonic inspection and measurement of spleen thickness and size of the treatment groups were more obvious than those of the control group (P<0.05). conclusions ADV combined with Anluohuaxian pills in treatment HBV related-active cirrhosis can obviously anti-ifbrosis and is better than solely using ADV.
